Stockscreener 앱 받기
145.30
1.56%
-2.30
시간 외 거래:
146.20
0.90
+0.62%
전일 마감가:
$147.60
열려 있는:
$147.98
하루 거래량:
3.40M
Relative Volume:
1.41
시가총액:
$31.32B
수익:
$606.42M
순이익/손실:
$-1.28B
주가수익비율:
-22.69
EPS:
-6.403
순현금흐름:
$-997.58M
1주 성능:
+6.84%
1개월 성능:
-2.70%
6개월 성능:
+6.04%
1년 성능:
+87.03%
1일 변동 폭
$142.59
$149.20
1주일 범위
$137.19
$149.88
52주 변동 폭
$60.40
$212.75
Insmed Inc Stock (INSM) Company Profile
명칭
Insmed Inc
전화
908-977-9900
주소
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
145.30 | 31.32B | 606.42M | -1.28B | -997.58M | -6.403 |
VRTX
Vertex Pharmaceuticals Inc
|
433.07 | 110.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
737.71 | 77.99B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
691.40 | 42.91B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
317.36 | 42.09B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
283.03 | 31.42B | 5.36B | 287.73M | 924.18M | 2.5229 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 재개 | Jefferies | Buy |
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2026-01-23 | 개시 | Roth Capital | Buy |
| 2025-12-19 | 재개 | Truist | Buy |
| 2025-12-04 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-10-28 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-08-20 | 개시 | William Blair | Outperform |
| 2025-08-13 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | 개시 | Jefferies | Buy |
| 2025-02-25 | 개시 | RBC Capital Mkts | Outperform |
| 2024-04-23 | 개시 | Truist | Buy |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-07-26 | 개시 | Guggenheim | Buy |
| 2022-12-09 | 개시 | Mizuho | Buy |
| 2022-12-07 | 개시 | Barclays | Overweight |
| 2022-11-18 | 개시 | BofA Securities | Buy |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2021-12-06 | 개시 | JP Morgan | Overweight |
| 2021-10-19 | 재개 | Monness Crespi & Hardt | Buy |
| 2021-10-19 | 재개 | Morgan Stanley | Overweight |
| 2021-10-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-10-12 | 재개 | Stifel | Buy |
| 2019-09-03 | 개시 | Goldman | Buy |
| 2019-04-09 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-15 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-01-02 | 개시 | Canaccord Genuity | Buy |
| 2018-08-06 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | 개시 | Goldman | Neutral |
| 2018-04-23 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | 개시 | Morgan Stanley | Overweight |
| 2018-01-18 | 개시 | Credit Suisse | Neutral |
| 2017-09-05 | 재확인 | Evercore ISI | Outperform |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-07-11 | 개시 | Robert W. Baird | Outperform |
| 2016-03-15 | 개시 | Stifel | Buy |
| 2015-11-09 | 다운그레이드 | UBS | Buy → Neutral |
| 2015-10-06 | 재확인 | H.C. Wainwright | Buy |
| 2015-06-09 | 개시 | Citigroup | Neutral |
| 2014-03-26 | 재확인 | HC Wainwright | Buy |
모두보기
Insmed Inc 주식(INSM)의 최신 뉴스
SG Americas Securities LLC Buys 49,356 Shares of Insmed, Inc. $INSM - MarketBeat
Positive Phase 3b study update sees Insmed stock drop 1.56% - Traders Union
Nordea Investment Management AB Makes New Investment in Insmed, Inc. $INSM - MarketBeat
Vanguard disaggregates holdings; Insmed (NASDAQ: INSM) shows 0 shares - Stock Titan
Assenagon Asset Management S.A. Sells 22,419 Shares of Insmed, Inc. $INSM - MarketBeat
INSM Stock: HC Wainwright & Co. Raises Price Target to $245 | IN - GuruFocus
Insmed (NASDAQ:INSM) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
H.C. Wainwright raises Insmed stock price target on ARIKAYCE data - Investing.com
Insmed (INSM) poised for 2026 upside with potential $1.3B Arikayce sales boost, Roth/MKM initiates buy - MSN
INSM Stock Price, Quote & Chart | INSMED INC (NASDAQ:INSM) - ChartMill
Insmed shares rise on positive results from ARIKAYCE Phase 3b study - MSN
Insmed jumps 6.6% as attention returns to upcoming ENCORE readout for ARIKAYCE - Quiver Quantitative
Insmed CEO reveals Japan patient population exceeds US market for lung disease - AOL.com
Insmed (NASDAQ:INSM) Price Target Raised to $206.00 at Mizuho - MarketBeat
INSM Stock: Mizuho Raises Price Target Amid Stable Outlook | INS - GuruFocus
Insmed (NASDAQ:INSM) Price Target Upgrades Drive Nasdaq Index Focus - Kalkine Media
Wells Fargo Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $177 - Moomoo
INSM: Leerink Partners Raises Price Target, Maintains Outperform Rating | INSM Stock News - GuruFocus
INSM: Wells Fargo Raises Price Target to $177, Reaffirms Overwei - GuruFocus
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ionis Pharmaceuticals (IONS), GE Healthcare Technologies Inc (GEHC) and Insmed (INSM) - The Globe and Mail
B of A Securities Maintains Buy Rating for INSM, Raises Price Ta - GuruFocus
Insmed Stock Hits Day Low of $135.73 Amid Price Pressure - Markets Mojo
Apogee Therapeutics, Insmed, Sunoco - TradingView
Insmed (NASDAQ:INSM) Price Target Raised to $215.00 at Leerink Partners - MarketBeat
A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $143.69 to $243 - Moomoo
INSM shares rise following Arikayce's successful outcome in label expansion trial - Bitget
Stifel Nicolaus Issues Positive Forecast for Insmed (NASDAQ:INSM) Stock Price - MarketBeat
INSM: Stifel Raises Price Target, Continues Buy Rating | INSM St - GuruFocus
Mizuho raises Insmed stock price target on positive trial data By Investing.com - Investing.com Canada
Mizuho raises Insmed stock price target on positive trial data - Investing.com
Mizuho Securities Maintains Insmed(INSM.US) With Buy Rating, Raises Target Price to $206 - Moomoo
INSM Stock Gains After Arikayce Hits Goal in Label Expansion Study - TradingView
Bank of America Forecasts Strong Price Appreciation for Insmed (NASDAQ:INSM) Stock - MarketBeat
Insmed eyes Arikayce label expansion on Phase IIIb lung disease success - Yahoo Finance
Stifel raises Insmed stock price target on positive trial data - Investing.com
Mizuho Lifts Price Target on Insmed to $206 From $204, Keeps Outperform Rating - marketscreener.com
Stocks Flashing Renewed Technical Strength: Insmed - Investor's Business Daily
Insmed reports positive Phase 3b trial results for MAC lung disease drug - au.investing.com
Insmed’s New Lung Disease Study Data A Win For Company, Says Analyst - Stocktwits
A Look At Insmed (INSM) Valuation After Positive ENCORE Phase 3b ARIKAYCE Data - Yahoo Finance
Analyst weighs patent cliff risks against Insmed’s (INSM) growth story - MSN
Insmed CEO on its Arikayce drug after shares surge on trial results - MSN
Insmed Shares Climb on Positive Results for Arikayce - marketscreener.com
Market movers: Palantir Technologies, Insmed, Synopsys… - Proactive financial news
Insmed Announces Positive Phase 3b ENCORE Results for ARIKAYCE in MAC Lung Disease, Plans FDA Supplemental NDA Filing in 2026 - Minichart
BofA raises Insmed stock price target on positive trial data By Investing.com - Investing.com Canada
Insmed (INSM) Achieves Milestone with Positive Phase 3 ENCORE Tr - GuruFocus
Insmed Lung Infection Therapy Data Impresses, Analyst Sees Approval Path - Benzinga
Insmed ENCORE Phase 3 Trial Hits Primary Endpoint; ARIKAYCE Drives Strong MAC Culture Conversion Gains - MarketBeat
Insmed (INSM): ENCORE Phase 3 Success Expands MAC Lung Disease Opportunity and Underscores Arikayce Upside - TipRanks
Insmed rises on late-stage trial results for Arikayce for lung infection - Seeking Alpha
Insmed Inc (INSM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.20%
2.04%
자본화:
|
볼륨(24시간):